Vermillion to Report Third Quarter 2015 Financial Results and Host Investor Conference Call on November 12

AUSTIN, Texas, Oct. 29, 2015 /PRNewswire/ -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today it will report its third quarter 2015 financial results on Thursday, November 12, 2015, followed by an investor conference call and webcast at 8:30am Eastern.

About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic disease. The company's lead diagnostics in the United States, OVA1®, and in the European Union, Overa®, are blood tests for pre-surgical assessment of ovarian tumors for malignancy, each using an innovative algorithmic approach. Overa and OVA1, which was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, represent a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
[email protected]

SOURCE Vermillion, Inc.

Related Links

http://www.vermillion.com